Bryanna L Norden

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 18

Top Topics

Tyrosine Kinase

Sensitive Detection

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer discovery (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer discovery (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Ryan B Corcoran, Khanh T Do, Jeong Eun Kim, James M Cleary, Aparna Raj Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer T Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen X Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu, Geoffrey I Shapiro
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer discovery 14 (5) (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer discovery 14 (5) (2024)
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer discovery 14 (5) (2024)
Martin S Taylor, Connie Wu, Peter C Fridy, Stephanie J Zhang, Yasmeen Senussi, Justina Clarinda Wolters, Tatiana Cajuso, Wen-Chih Cheng, John D Heaps, Bryant D Miller, Kei Mori, Limor Cohen, Hua Jiang, Kelly R Molloy, Brian T Chait, Michael G Goggins, Irun Bhan, Joseph W Franses, Xiaoyu Yang, Mary-Ellen Taplin, Xinan Wang, David Chistopher Christiani, Bruce E Johnson, Matthew L Meyerson, Ravindra Uppaluri, Ann Marie Egloff, Elyssa N Denault, Laura M Spring, Tian-Li Wang, Ie-Ming Shih, Jennifer E Fairman, Euihye Jung, Kshitij S Arora, Osman H Yilmaz, Sonia Cohen, Tatyana Sharova, Gary Chi, Bryanna L Norden, Yuhui Song, Linda T Nieman, Leontios Pappas, Aparna Raj Parikh, Matthew R Strickland, Ryan B Corcoran, Tomas Mustelin, George Eng, Ömer H Yilmaz, Ursula A Matulonis, Steven J Skates, Bo R Rueda, Ronny Drapkin, Samuel J Klempner, Vikram Deshpande, David Tsai Ting, Michael P Rout, John LaCava, David R Walt, Kathleen H Burns
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Cancer discovery (2023)
Qibiao Wu, Haley Ellis, Giulia Siravegna, Alexa G Michel, Bryanna L Norden, Ferran Fece de la Cruz, Eranga Roshan Balasooriya, Yuanli Zhen, Vanessa Silva Silveira, Jianwei Che, Ryan B Corcoran, Nabeel El-Bardeesy
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg M Wulf, Aditya Bardia, Laura M Spring, Steven Jay Isakoff, Jochen K Lennerz, Levi Pierce, Ermira Pazolli, Gad A Getz, Ryan B Corcoran, Dejan Juric
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer discovery (2023)